IP Library Granted Patent US 8,318,779
Granted Patent B2
US 8,318,779 · App. 12/300,211 · Granted Nov 27, 2012

Lysine related derivatives as HIV aspartyl protease inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,318,779
App. No.
12/300,211
Granted
Nov 27, 2012
Kind
B2
Abstract

The present invention concerns lysine related derivatives, their use as protease inhibitors, in particular as HIV aspartyl protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present lysine related derivatives with another anti retroviral agent. It further relates to their use in assays as reference compounds or as reagents.

Claims (59)

1. A compound of formula (I)

or when the compound of formula I comprises an amino group, a pharmaceutically acceptable ammonium salt thereof,

wherein n is 3 or 4,

wherein X is H and Y is a straight or branched alkyl group of 1 to 6 carbon atoms substituted with a nitrogen

or

wherein X and Y are the same and are each a straight or branched alkyl group of 1 to 6 carbon atoms substituted with a nitrogen,

wherein R 1 is selected from the group consisting of a straight alkyl group of 1 to 6 carbon atoms, a branched alkyl group of 3 to 6 carbon atoms, a cycloalkylalkyl group having 3 to 6 carbon atoms in the cycloalkyl part thereof and 1 to 3 carbon atoms in the alkyl part thereof,

wherein R 2 is selected from the group consisting of H, a straight alkyl group of 1 to 6 carbon atoms, a branched alkyl group of 3 to 6 carbon atoms, a cycloalkyl group of 3 to 6 carbon atoms, and a group of formula R 2A —CO—, R 2A being selected from the group consisting of a straight or branched alkyl group of 1 to 6 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms, a cycloalkylalkyl group having 3 to 6 carbon atoms in the cycloalkyl part thereof and 1 to 3 carbon atoms in the alkyl part thereof, an alkyloxy group of 1 to 6 carbon atoms, tetrahydro-3-furanyloxy, —CH 2 OH, —CF 3 , —CH 2 CF 3 , —CH 2 CH 2 CF 3 , pyrrolidinyl, piperidinyl, 4-morpholinyl, CH 3 O 2 C—, CH 3 O 2 CCH 2 —, Acetyl-OCH 2 CH 2 —, HO 2 CCH 2 —, 3-hydroxyphenyl, 4-hydroxyphenyl, 4-CH 3 OC 6 H 4 CH 2 —, CH 3 NH—, (CH 3 ) 2 N—, (CH 3 CH 2 ) 2 N—, (CH 3 CH 2 CH 2 ) 2 N—, HOCH 2 CH 2 NH—, CH 3 OCH 2 O—, CH 3 OCH 2 CH 2 O—, C 6 H 5 CH 2 O—, 2-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl-, 2-pyrazinyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 2-quinoxalinyl, a phenyl group of formula

a picolyl group selected from the group consisting of

a picolyloxy group selected from the group consisting of

a substituted pyridyl group selected from the group consisting of

a group selected from the group consisting of

wherein X′ and Y′, the same or different, are selected from the group consisting of H, a straight alkyl group of 1 to 6 carbon atoms, a branched alkyl group of 3 to 6 carbon atoms, a cycloalkyl group of 3 to 6 carbon atoms, F, Cl, Br, I, —CF 3 , —NO 2 , —NR 4 R 5 , —NHCOR 4 , —OR 4 , —SR 4 , —COOR 4 , —COR 4 and —CH 2 OH,

wherein R 4 and R 5 , the same or different, are selected from the group consisting of H, a straight alkyl group of 1 to 6 carbon atoms, a branched alkyl group of 3 to 6 carbon atoms, and a cycloalkyl group of 3 to 6 carbon atoms,

wherein R 3 is selected from the group consisting of

a diphenylmethyl group of formula IV

a naphthyl-1-CH 2 — group of formula V

a naphthyl-2-CH 2 — group of formula VI

a biphenylmethyl group of formula VII

and an (anthracen-9-yl)-methyl group of formula VIII

2. A compound of formula (II)

and when the compound of formula II comprises an amino group, pharmaceutically acceptable ammonium salts thereof,

wherein n is 3 or 4,

wherein X is H and Y is a straight or branched alkyl group of 1 to 6 carbon atoms substituted with a nitrogen

or

wherein X and Y are the same and are each a straight or branched alkyl group of 1 to 6 carbon atoms substituted with a nitrogen,

wherein R 1 is selected from the group consisting of a straight alkyl group of 1 to 6 carbon atoms, a branched alkyl group of 3 to 6 carbon atoms, a cycloalkylalkyl group having 3 to 6 carbon atoms in the cycloalkyl part thereof and 1 to 3 carbon atoms in the alkyl part thereof,

wherein R 2 is selected from the group consisting of H, a straight alkyl group of 1 to 6 carbon atoms, a branched alkyl group of 3 to 6 carbon atoms, a cycloalkyl group of 3 to 6 carbon atoms, and a group of formula R 2A —CO—, R 2A being selected from the group consisting of a straight or branched alkyl group of 1 to 6 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms, a cycloalkylalkyl group having 3 to 6 carbon atoms in the cycloalkyl part thereof and 1 to 3 carbon atoms in the alkyl part thereof, an alkyloxy group of 1 to 6 carbon atoms, tetrahydro-3-furanyloxy, —CH 2 OH, —CF 3 , —CH 2 CF 3 , —CH 2 CH 2 CF 3 , pyrrolidinyl, piperidinyl, 4-morpholinyl, CH 3 O 2 C—, CH 3 O 2 CCH 2 —, Acetyl-OCH 2 CH 2 —, HO 2 CCH 2 —, 3-hydroxyphenyl, 4-hydroxyphenyl, 4-CH 3 OC 6 H 4 —CH 2 —, CH 3 NH—, (CH 3 ) 2 N—, (CH 3 CH 2 ) 2 N—, (CH 3 CH 2 CH 2 ) 2 N—, HOCH 2 CH 2 NH—, CH 3 OCH 2 O—, CH 3 OCH 2 CH 2 O—, C 6 H 5 CH 2 O—, 2-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl-, 2-pyrazinyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 2-quinoxalinyl, a phenyl group of formula

a picolyl group selected from the group consisting of

a picolyloxy group selected from the group consisting of

a substituted pyridyl group selected from the group consisting of

a group selected from the group consisting of

wherein X′ and Y′, the same or different, are selected from the group consisting of H, a straight alkyl group of 1 to 6 carbon atoms, a branched alkyl group of 3 to 6 carbon atoms, a cycloalkyl group of 3 to 6 carbon atoms, F, Cl, Br, I, —CF 3 , —NO 2 , —NR 4 R 5 , —NHCOR 4 , —OR 4 , —SR 4 , —COOR 4 , —COR 4 and —CH 2 OH,

wherein R 4 and R 5 , the same or different, are selected from the group consisting of H, a straight alkyl group of 1 to 6 carbon atoms, a branched alkyl group of 3 to 6 carbon atoms, and a cycloalkyl group of 3 to 6 carbon atoms,

wherein R 3 is selected from the group consisting of

a diphenylmethyl group of formula IV

a naphthyl-1-CH 2 — group of formula V

a naphthyl-2-CH 2 — group of formula VI

a biphenylmethyl group of formula VII

and an (anthracen-9-yl)-methyl group of formula VIII

3. A compound according to claim 2 wherein R 1 is iso-butyl and n is 4.

4. A compound according to claim 3 wherein R 2 is CH 3 O 2 C—.

5. A compound according to claim 4 wherein R 3 is

6. A compound according to claim 5 wherein X is H and Y is —CH 2 NH 2 .

7. A compound having the formula (III)

8. A pharmaceutical composition comprising an effective amount of at least one compound as claimed in claim 1 and a pharmaceutically tolerable excipient.

9. A composition comprising at least (a) a compound of formula (I), (II) or (III) as claimed in claim 1 and, (b) a second antiretroviral agent for the simultaneous, separate or sequential use.

10. A pharmaceutical composition comprising an effective amount of at least one compound as claimed in claim 2 and a pharmaceutically tolerable excipient.

11. A pharmaceutical composition comprising an effective amount of at least one compound as claimed in claim 3 and a pharmaceutically tolerable excipient.

12. A pharmaceutical composition comprising an effective amount of at least one compound as claimed in claim 4 and a pharmaceutically tolerable excipient.

13. A pharmaceutical composition comprising an effective amount of at least one compound as claimed in claim 5 and a pharmaceutically tolerable excipient.

14. A pharmaceutical composition comprising an effective amount of at least one compound as claimed in claim 6 and a pharmaceutically tolerable excipient.

15. A pharmaceutical composition comprising an effective amount of at least one compound as claimed in claim 7 and a pharmaceutically tolerable excipient.

16. A composition comprising at least (a) a compound of formula (I), (II) or (III) as claimed in claim 2 and, (b) a second antiretroviral agent for the simultaneous, separate or sequential use.

17. A composition comprising at least (a) a compound of formula (I), (II) or (III) as claimed in claim 3 and, (b) a second antiretroviral agent for the simultaneous, separate or sequential use.

18. A composition comprising at least (a) a compound of formula (I), (II) or (III) as claimed in claim 4 and, (b) a second antiretroviral agent for the simultaneous, separate or sequential use.

19. A composition comprising at least (a) a compound of formula (I), (II) or (III) as claimed in claim 5 and, (b) a second antiretroviral agent for the simultaneous, separate or sequential use.

20. A composition comprising at least (a) a compound of formula (I), (II) or (III) as claimed in claim 6 and, (b) a second antiretroviral agent for the simultaneous, separate or sequential use.

21. A composition comprising at least (a) a compound of formula (I), (II) or (III) as claimed in claim 7 and, (b) a second antiretroviral agent for the simultaneous, separate or sequential use.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: JANSSEN R & D IRELAND
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 035496/0382 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2012
From: JONCKERS, TIM H.M.; DIERYNCK, INGE; LAST, STEFAAN J.; DE KOCK, HERMAN A.
To: TIBOTEC BVBA
Reel/Frame 028438/0229 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2012
From: TIBOTEC BVBA
To: TIBOTEC PHARMACEUTICALS LTD.
Reel/Frame 028438/0248 →
CHANGE OF NAME Recorded Jun 25, 2012
From: TIBOTEC PHARMACEUTICALS LTD.
To: JANSSEN R&D IRELAND
Reel/Frame 028438/0301 →